


SEE THE DIFFERENCE, MAKE A DIFFERENCE.

EFFECTIVE ENHANCEMENT AT HALF THE GD DOSE.*1-3

CONTRAST AGENT	Gadopiclenol (VUEWAY+ Elucirem™)	Gadobenate dimeglumine (MULTIHANCE)	Gadoteridol (PROHANCE)	Gadobutrol (Gadovist + Pixxoscan)	Gadoteric acid (Dotarem + Clariscan™)
RELAXIVITY	HIGHEST ^{4†}	HIGH ^{4*}	STANDARD	STANDARD ⁵	STANDARD ⁵
Gd DOSE (mmol/kg)	0.05	0.05 [#]	0.1	0.1**	0.1
Volume DOSE (mL/kg)	0.1	0.1	0.2	0.1	0.2
CONCENTRATION	STANDARD	STANDARD	STANDARD	DOUBLE	STANDARD
					

Before use, please refer to your locally approved SmPC.

The individual who appears is for illustrative purposes.
The person depicted is a model and not a real healthcare professional.

VISIT [Bracco.com](https://www.bracco.com) FOR MORE INFORMATION



A POTENT HIGH-RELAXIVITY AGENT CAN PROVIDE SIMILAR DIAGNOSTIC EFFICACY EVEN WHEN ADMINISTERED AT A LOWER GD DOSE VS. A STANDARD-RELAXIVITY GBCA[§] GIVEN AT A HIGHER DOSE⁵⁻⁷



BECAUSE HALF THE GD DOSE IS ONLY HALF THE STORY*

Body weight in kilograms (kg)	Quantity in millimoles (mmol)
10	0.5
20	1.0
30	1.5
40	2.0
50	2.5
60	3.0
70	3.5
80	4.0
90	4.5
100	5.0
110	5.5
120	6.0

At a minimum, VUEWAY® provides comparable contrast enhancement at half the Gd dose vs. another GBCA at 0.1 mmol/kg¹⁻³

VUEWAY® (gadopiclenol)	Characteristics
RELAXIVITY (potency)	HIGHEST ^{4†} (r1 of 12.8 in serum at 1.5T – is triple that of Dotarem ^{®4})
Gd DOSE	0.05 mmol/kg (Half the dose*)
Volume DOSE	0.1 mL/kg (Same as Gadovist [®])
CONCENTRATION	STANDARD (0.5M)

Body weight in kilograms (kg)	Volume in milliliters (ml)
10	1
20	2
30	3
40	4
50	5
60	6
70	7
80	8
90	9
100	10
110	11
120	12

VUEWAY® offers simplified weight-adjusted dosing volumes¹

*Half the gadolinium dose compared to other macrocyclic GBCAs at a Gd dose of 0.1 mmol/kg in approved indications.

†Highest Relaxivity GBCA: a significantly higher r1 (>100%) than the reference value of Magnevist[®] at 1.5T, i.e. >8.2 Lmmol⁻¹·s⁻¹.⁸⁻¹¹

‡High-Relaxivity GBCAs: an r1 of 6.3-8.2 Lmmol⁻¹·s⁻¹ or 50 to 100% higher than the reference value of Magnevist[®] at 1.5T.⁸⁻¹¹

§Standard Relaxivity: an r1 of 1.9-6.2 Lmmol⁻¹·s⁻¹, i.e. similar (+/- 50%) to the reference value of Magnevist[®] at 1.5T (4.1 Lmmol⁻¹·s⁻¹).⁸⁻¹¹

¶MultiHance[®] has been indicated at an approved dose of 0.05 mmol/kg for liver scans in the EU since 2017.¹²

**A dose of 0.075 mmol gadobutrol per kg body weight (Gadovist[®] or Pixxoscan[®]) may be administered at minimum for imaging of the CNS.^{13,14}

GBCA: gadolinium-based contrast agent; Gd: gadolinium; MRI: magnetic resonance imaging.

1. VUEWAY[®] SmPC 2024.
2. Loevner L, et al. Invest Radiol. 2023 May ;58(5):307-313.
3. Kuhl C, et al. Radiol. 2023 Jul;308(1).
4. Robic C, et al. Invest Radiol. 2019;54:475-484.
5. Tweedle MF, et al. Supplement to Applied Radiology; May 2014.
6. Jacques V, et al. Invest Radiol. 2010 Oct;45(10):613-624.
7. Lancelot E, et al. Invest Radiol. 2020 Sep;55(9):578-588.
8. Rohrer M, et al. Invest Radiol. 2005;40:715-724.
9. Pintaske J, et al. Invest Radiol. 2006;41: 213-221 (and Erratum Invest Radiol. 2006;41: 859).

10. Giesel FL, et al. Invest Radiol. 2006;41:222-228.
11. Rowley H, et al. Applied Radiology 2022 Aug; Supplement to 51(4):5-16.
12. MultiHance[®] SmPC 2021.
13. Gadovist[®] SmPC 2022.
14. Pixxoscan[®] SmPC 2023.